Elkik F, Claudel S, Carcone B, Grippon P
Hôpital St. Louis, Paris, France.
J Cardiovasc Pharmacol. 1991 May;17(5):685-91. doi: 10.1097/00005344-199105000-00001.
The maximum blood pressure (BP) decrease obtained after dose titration with calcium antagonists is said to be greater in older patients. Because the dose necessary to achieve this maximum effect may also vary, it is not clear whether the sensitivity to treatment is actually increased in older patients. We evaluated the possible influence of pretreatment BP, age, and weight on the BP and heart rate (HR) response to 14-day treatment with a fixed dose of 120 mg diltiazem twice daily (b.i.d.) in 231 hypertensive patients aged 24-82 years (44 +/- 27). Diltiazem decreased BP from 171 +/- 1/103 +/- 7 to 156 +/- 1/91 +/- 1 mm Hg. Decreases in both systolic and diastolic BP (SBP, DBP) were related to their pretreatment values (p less than 0.0001 for both). Although pretreatment SBP was related to age (p less than 0.0001), its decrease with diltiazem was not. Neither pretreatment DBP nor its decrease with diltiazem was related to age; BP decrease was not superior in elderly patients (aged greater than 60 years) as compared with that in younger patients (SBP -16 +/- 2 vs. -15 +/- 1 mm Hg, NS; DBP -13 +/- 1 vs. -12 +/- 1 mm Hg, NS). In conclusion, the response to this average dose of diltiazem is related to pretreatment BP and is not affected by patient's age. Because this result is at variance with the concept that calcium antagonists are more effective in the elderly, this concept should not be used as a general therapeutic guideline.
据说,使用钙拮抗剂进行剂量滴定后,老年患者的最大血压(BP)降幅更大。由于达到这种最大效果所需的剂量也可能有所不同,因此尚不清楚老年患者对治疗的敏感性是否真的有所提高。我们评估了治疗前血压、年龄和体重对231名年龄在24 - 82岁(44±27岁)的高血压患者每日两次(bid)服用固定剂量120 mg地尔硫䓬进行14天治疗时血压和心率(HR)反应的可能影响。地尔硫䓬使血压从171±1/103±7降至156±1/91±1 mmHg。收缩压和舒张压(SBP、DBP)的下降均与其治疗前值相关(两者p均<0.0001)。尽管治疗前SBP与年龄相关(p<0.0001),但其用地尔硫䓬治疗后的下降与年龄无关。治疗前DBP及其用地尔硫䓬治疗后的下降均与年龄无关;老年患者(年龄>60岁)的血压降幅与年轻患者相比并无优势(SBP -16±2 vs. -15±1 mmHg,无显著性差异;DBP -13±1 vs. -12±1 mmHg,无显著性差异)。总之,对地尔硫䓬这一平均剂量的反应与治疗前血压相关,不受患者年龄影响。由于这一结果与钙拮抗剂在老年人中更有效的观念不一致,因此该观念不应作为一般治疗指南。